RCKT — Rocket Pharmaceuticals Balance Sheet
0.000.00%
- $359.30m
- $157.81m
Annual balance sheet for Rocket Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 483 | 389 | 356 | 373 | 372 |
| Prepaid Expenses | |||||
| Total Current Assets | 487 | 392 | 364 | 378 | 378 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 70.6 | 72.3 | 77.6 | 87.6 | 83.3 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 591 | 497 | 552 | 566 | 528 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 32.6 | 22.2 | 39.2 | 48.5 | 40.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 87.3 | 42.3 | 62.1 | 73.8 | 64.5 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 504 | 455 | 490 | 493 | 463 |
| Total Liabilities & Shareholders' Equity | 591 | 497 | 552 | 566 | 528 |
| Total Common Shares Outstanding |